Novel agents, such as sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, are considered to provide potential benefits for patients with heart failure due to their unique mechanisms of action (7). The gene discussed is SLC5A2; the disease is heart failure.